125 related articles for article (PubMed ID: 38258295)
41. Substance P-saporin down-regulates substance P receptor immunoreactive sensory dorsal root ganglion neurons innervating the lumbar intervertebral discs in rats.
Ohtori S; Inoue G; Koshi T; Ito T; Doya H; Moriya H; Takahashi K
Spine (Phila Pa 1976); 2006 Dec; 31(26):2987-91. PubMed ID: 17172993
[TBL] [Abstract][Full Text] [Related]
42. The differential catalytic activity of ribosome-inactivating proteins saporin 5 and 6 is due to a single substitution at position 162.
Ghosh P; Batra JK
Biochem J; 2006 Nov; 400(1):99-104. PubMed ID: 16831127
[TBL] [Abstract][Full Text] [Related]
43. Photochemically stimulated drug delivery increases the cytotoxicity and specificity of EGF-saporin.
Weyergang A; Selbo PK; Berg K
J Control Release; 2006 Mar; 111(1-2):165-73. PubMed ID: 16466823
[TBL] [Abstract][Full Text] [Related]
44. Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells.
Vago R; Marsden CJ; Lord JM; Ippoliti R; Flavell DJ; Flavell SU; Ceriotti A; Fabbrini MS
FEBS J; 2005 Oct; 272(19):4983-95. PubMed ID: 16176271
[TBL] [Abstract][Full Text] [Related]
45. Effects of lateral hypothalamic lesion with the neurotoxin hypocretin-2-saporin on sleep in Long-Evans rats.
Gerashchenko D; Blanco-Centurion C; Greco MA; Shiromani PJ
Neuroscience; 2003; 116(1):223-35. PubMed ID: 12535955
[TBL] [Abstract][Full Text] [Related]
46. Augmentation of antiproliferative and antitumor effect on human cancer cells in combined use of electroporation with a plant toxin, saporin.
Mashiba H; Ozaki Y; Ikuno S; Matsunaga K
Cancer Biother Radiopharm; 2001 Dec; 16(6):495-9. PubMed ID: 11789026
[TBL] [Abstract][Full Text] [Related]
47. Effects of hypocretin-saporin injections into the medial septum on sleep and hippocampal theta.
Gerashchenko D; Salin-Pascual R; Shiromani PJ
Brain Res; 2001 Sep; 913(1):106-15. PubMed ID: 11532254
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor.
Porreca F; Burgess SE; Gardell LR; Vanderah TW; Malan TP; Ossipov MH; Lappi DA; Lai J
J Neurosci; 2001 Jul; 21(14):5281-8. PubMed ID: 11438603
[TBL] [Abstract][Full Text] [Related]
49. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
50. Preferential destruction of cerebellar Purkinje cells by OX7-saporin.
Angner RT; Kelly RM; Wiley RG; Walsh TJ; Reuhl KR
Neurotoxicology; 2000 Jun; 21(3):395-403. PubMed ID: 10894129
[TBL] [Abstract][Full Text] [Related]
51. Deficit in selective and divided attention associated with cholinergic basal forebrain immunotoxic lesion produced by 192-saporin; motoric/sensory deficit associated with Purkinje cell immunotoxic lesion produced by OX7-saporin.
Waite JJ; Wardlow ML; Power AE
Neurobiol Learn Mem; 1999 May; 71(3):325-52. PubMed ID: 10196110
[TBL] [Abstract][Full Text] [Related]
52. Behavioral and neurobiological alterations induced by the immunotoxin 192-IgG-saporin: cholinergic and non-cholinergic effects following i.c.v. injection.
Walsh TJ; Kelly RM; Dougherty KD; Stackman RW; Wiley RG; Kutscher CL
Brain Res; 1995 Dec; 702(1-2):233-45. PubMed ID: 8846082
[TBL] [Abstract][Full Text] [Related]
53. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis.
Bergamaschi G; Perfetti V; Tonon L; Novella A; Lucotti C; Danova M; Glennie MJ; Merlini G; Cazzola M
Br J Haematol; 1996 Jun; 93(4):789-94. PubMed ID: 8703804
[TBL] [Abstract][Full Text] [Related]
54. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
[TBL] [Abstract][Full Text] [Related]
55. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
Tazzari PL; Zhang S; Chen Q; Sforzini S; Bolognesi A; Stirpe F; Xie H; Moretta A; Ferrini S
Br J Cancer; 1993 Jun; 67(6):1248-53. PubMed ID: 8512810
[TBL] [Abstract][Full Text] [Related]
56. In vivo and in vitro uptake of an anti-CD30/saporin immunotoxin by rat liver parenchymal and nonparenchymal cells.
Battelli MG; Buonamici L; Bolognesi A; Stirpe F
Hepatology; 1994 Oct; 20(4 Pt 1):940-7. PubMed ID: 7927236
[TBL] [Abstract][Full Text] [Related]
57. Fibroblast growth factor complexed to the cytotoxin saporin is growth inhibitory but not cytotoxic for embryonal carcinoma cells.
Miller K; Wilder PJ; Rizzino A
Cytotechnology; 1993; 13(2):69-78. PubMed ID: 7764580
[TBL] [Abstract][Full Text] [Related]
58. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
[TBL] [Abstract][Full Text] [Related]
60. Behavioral, biochemical, histological, and electrophysiological effects of 192 IgG-saporin injections into the basal forebrain of rats.
Wenk GL; Stoehr JD; Quintana G; Mobley S; Wiley RG
J Neurosci; 1994 Oct; 14(10):5986-95. PubMed ID: 7523630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
